Crescent BioPharma (CBIO) GC Barbara Bispham Sells 620 Shares

What Happened

• Barbara Harlin Bispham, General Counsel and Corporate Secretary of Crescent BioPharma (CBIO), sold 620 shares on 2026-09-16 in an open-market/private sale for aggregate proceeds of $11,098. The filing reports a weighted-average sale price of $17.90 per share (individual trade prices ranged $17.10–$19.17).

Key Details

• Transaction date: 2026-09-16; Form 4 filed: 2026-09-18 (filed within the usual two-business-day Form 4 window).
• Shares sold: 620; weighted-average price: $17.90; total proceeds: $11,098.
• Price range: $17.10 to $19.17 across multiple trades (per footnote F2).
• Footnote F1: Shares were automatically sold to satisfy tax withholding on restricted stock units that vested (RSUs granted 2025-12-15); sales effected under a Rule 10b5-1 instruction adopted 2026-02-25, solely to cover taxes.
• Shares owned after the transaction: not specified in the provided filing.
• Role noted in Remarks: General Counsel and Corporate Secretary.

Context

• This was a tax-withholding sale tied to RSU vesting, executed under a pre-established 10b5-1 plan—common, routine insider sales and not necessarily an indicator of sentiment about the company. The filer will provide a per-price breakdown upon request (per the filing).